• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Investing

Tilray secures new cannabis cultivation license in Germany: Is it time to buy TLRY?

by July 22, 2024
written by July 22, 2024

Tilray Brands Inc (NASDAQ: TLRY) has made a significant stride in its European operations by securing a new cannabis cultivation license in Germany. 

This development, under the country’s new Cannabis Act (MedCanG), is set to substantially boost the production capacity of Tilray’s Aphria RX GmbH facility in Berlin. 

This news comes at a crucial time for the New York-based firm, which has seen its stock decline by 35% since early April.

What the new license means for Tilray stock

The new license is expected to increase Tilray’s production of medical cannabis by up to fivefold, according to the company’s press release on Monday. 

This expansion is a pivotal move for Tilray, potentially aiding in the recovery of its stock. The license also allows Tilray to cultivate and produce up to 31 approved strains of cannabis, a significant increase from the previous limit of three strains. 

This will not only enhance the genetic diversity of Tilray’s products but also expand its product range in Germany’s medical cannabis market.

Denise Faltischek, Tilray’s Chief Strategy Officer, highlighted the importance of the new license, stating it will enable “greater access to some of the highest quality medical cannabis produced in Germany.” 

This development underscores Tilray’s commitment to expanding its footprint in the European market and positions the company to capitalize on Germany’s growing medical cannabis industry.

Positive market response and strategic importance

Investors have responded positively to the news, with Tilray’s stock rising approximately 3% at the time of writing on Monday. 

This uptick reflects investor confidence in the company’s strategic moves to strengthen its presence in Europe and enhance its production capabilities.

The new license comes at a critical juncture for Tilray, as the company is set to report its second-quarter earnings on July 29th. 

The timing of this announcement could provide a much-needed boost in investor sentiment ahead of the earnings report. In 2019, the German Federal Institute for Drugs and Medical Devices (BfArM) granted Aphria RX the most comprehensive permit for the cultivation of medical cannabis. 

The new Cannabis Act has significantly increased the use of medical cannabis in Germany, and Tilray is now well-positioned to fully capitalize on this market opportunity with its new license.

Financial outlook and market expectations

Tilray’s recent financial performance has been mixed. The company broke even on a per-share basis in the fourth quarter of 2023 but is expected to report a loss of 2 cents per share in the upcoming fourth quarter.

Investors will be closely watching for updates on Tilray’s outlook for free cash flow, which management previously indicated is unlikely to turn positive in 2024.

Earlier in July, analysts at Zuanic & Associates assumed coverage of Tilray stock with a “neutral” rating.

They cited the company’s potential to benefit from regulatory updates in overseas medical markets as a key factor. This new license in Germany could be a catalyst for Tilray to leverage these regulatory changes and improve its financial performance.

Tilray’s acquisition of a new cannabis cultivation license in Germany marks a significant step in the company’s strategic expansion in Europe. 

The anticipated increase in production capacity and product diversity positions Tilray to capitalize on Germany’s growing medical cannabis market. 

As the company prepares to report its second-quarter earnings, this development could help restore investor confidence and pave the way for future growth.

Watch here: https://www.youtube.com/embed/0UUrKOz49MA?feature=oembed

The post Tilray secures new cannabis cultivation license in Germany: Is it time to buy TLRY? appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Vance hits campaign trail as Harris team scrambles to consolidate Dem support
next post
House GOP demands Secret Service director face accountability in new resolution: ‘Must be fired now’

related articles

Asian markets open: Nikkei, Hang Seng fall on...

June 12, 2025

Aluminum and steel tariffs spark rise in secondary...

June 12, 2025

Airbus sees aviation boom ahead, global fleet to...

June 12, 2025

US-China trade talks and Washington’s decade-long effort to...

June 12, 2025

Europe markets open: Stoxx 600 dips as UK...

June 12, 2025

UK GDP falls by 0.3% in April as...

June 12, 2025

Gordon Brothers buys Poundland; pledges £80 mn for...

June 12, 2025

Air India plane crash: London-bound flight with 242...

June 12, 2025

Air India plane crash live update: Indian President...

June 12, 2025

Copper remains supported for now even as China...

June 12, 2025
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • SCOOP: Freedom Caucus threatens to force vote on Al Green measure if Johnson doesn’t act

    March 12, 2025
  • USDCHF and USDJPY: USDCHF creates a support zone

    August 23, 2024
  • Trump administration picks’ families have 1 thing in common

    November 21, 2024
  • Ethereum goes sideways on Wednesday above $2600

    September 25, 2024
  • Davos 2025: Collaborative Solutions for a Divided World

    January 24, 2025

Popular Posts

  • 1

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 2

    Elon and Vivek should tackle US funding for this boondoogle organization and score a multimillion dollar win

    December 4, 2024
  • 3

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 4

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024
  • 5

    Biden calls to ‘lower the temperature’ then bashes Trump in NAACP speech

    July 17, 2024

Categories

  • Economy (829)
  • Editor's Pick (5,006)
  • Investing (634)
  • Stock (809)

Latest Posts

  • John Kirby dodges grilling over plea agreement for 9/11 terrorists: ‘Didn’t hear an answer’

    August 4, 2024
  • CVS is under pressure and considering a breakup. Here’s why that could be risky.

    October 6, 2024
  • ‘War criminal Netanyahu’: ‘Squad’ members erupt over Israel’s ‘reckless’ strike on Iran

    June 13, 2025

Recent Posts

  • Ukraine to analyze fragments of missile fired by Russia capable of carrying nuclear warheads

    November 24, 2024
  • Jim Jordan details House GOP strategy to back up Trump in court: ‘Everything’s on the table’

    February 26, 2025
  • Long AON: capitalizing on bullish trends and strategic fundamentals for targeted upside potential

    January 9, 2025

Editor’s Pick

  • Trump blasts Harris as part of Truth Social flurry on what she ‘didn’t mention’ in DNC speech

    August 23, 2024
  • State Department denies lack of planning for withdrawal laid out in GOP-led Afghanistan report

    September 9, 2024
  • VP Harris could face more scrutiny from GOP if she assumes presidency: expert

    July 23, 2024
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock